CD19 and cancer: The approval of these four CD19-redirected CAR-T cells further highlights the clinical importance of CD19 in the context of cancer immunotherapy alongside accentuating the potential therapeutic benefits of CAR-T cells for the treatment of CD19-associated malignancies.